ArticleVaccines2023

A Phase 1, Randomized, Double-Blinded, Placebo-Controlled and Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the Intranasal DelNS1-nCoV-RBD LAIV for COVID-19 in Healthy Adults.

Ruiqi Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.